Pendekatan Diagnosis dan Tatalaksana Awal Kelainan Hematologi pada Anak dengan Penyakit Jantung Bawaan Sianotik
Sari
Penyakit Jantung Bawaan sianotik adalah kelainan jantung bawaan akibat pirau darah dari kanan ke kiri yang mengakibatkan penurunan saturasi oksigen dalam sirkulasi sistemik. Pada PJB sianotik yang belum dikoreksi dalam jangka waktu yang lama akan terjadi hiperviskositas dan eritropoesis sekunder. Polisitemia, koagulopati, trombositopenia, dan anemia defisiensi besi relatif merupakan masalah yang sering ditemui. Tatalaksana awal kelainan hematologi ini sangat penting dalam menurunkan morbiditas dan mortalitas anak dengan PJB sianotik. Pemberian suplementasi zat besi untuk anemia defisiensi besi relatif, phlebotomi untuk kondisi polisitemia serta berbagai tatalaksana kelainan hematologi lainnya masih sangat terbatas dan kontroversial.
Kata Kunci
Teks Lengkap:
PDFReferensi
Mukai N, Nakayama Y, Murakami S, dkk. Potential contribution of erythrocyte microRNA to secondary erythrocytosis and thrombocytopenia in congenital heart disease. Pediatr Res 2018;83:866-73.
Mukherjee S, Sharma M, Devgan A, dkk. Iron deficiency anemia in children with cyanotic congenital heart disease and effect on cyanotic spells. Med J Armed Forces India 2018;74:235-40.
Griesman J, Karahalios D, Prendergast C. Hematologic changes in cyanotic congenital heart disease: a review. Progress in Pediatric Cardiol 2020;56:101193.
Terlemez S, Tunao?lu FS, Gökta? T, dkk. The effects of iron treatment on viscosity in children with cyanotic congenital heart disease. Hematology 2017;22:30-5.
Animasahun BA, Itiola J, Adekunle MO. Comparison of erythrocyte indices and haematological indices as markers of iron status of lagos children with cyanotic congenital heart disease. Ann Blood 2020;5:1.
R Matter, I Ragab, A Roushdy, dkk. Determinants of platelet count in pediatric patients with congenital cyanotic heart disease: Role of immature platelet fraction. Congenit Heart Dis 2017;13:1-6.
H. Mohammadi, B. Ahranjani, E. Moghadam, dkk. Hematological indices in pediatric patients with acyanotic congenital heart disease : a cross-sectional study of 248 patients. Egypt J Med Hum Genet 2022;23:1-8.
Matter RM, Ragab IA, Roushdy AM, dkk. Determinants of platelet count in pediatric patients with congenital cyanotic heart disease: Role of immature platelet fraction. Congenit Heart Dis 2018;13:118-23.
Karanjkar A, Kapoor PM, Sharan S, dkk. A prospective randomized clinical trial of efficacy of algorithm-based point of care guided hemostatic therapy in cyanotic congenital heart disease surgical patients. J Card Crit Care 2019;03:08-16.
A. Pillai, S. Fazal, H. Babiker, Polycythemia. StatPearls Publishing; 2021.
Varma A, Sharma V, Damke S, dkk. Clinical presentation of cyanotic congenital heart diseases in the pediatric population. J Datta Meghe Inst Med Sci Univ 2020;15:7-11.
Rohit M, Shrivastava S. Acyanotic and cyanotic congenital heart diseases. Indian J Pediatr 2018;85:454-60.
Strauss RG. Transfusion of blood and blood components. Dalam: Kliegman RM, Stanton BF, St. Geme JW, Schor NF, Behrman RE, penyunting. Nelson textbook of pediatrics. Edisi ke-19. Philadelphia: WB Saunders; 2011. h.1727-32.
Spence MS, Balaratnam MS, Gatzoulis MA. The Lancet; Nov 3-Nov 9;2007.h.370.
Vecchio S, Leonardo P, Musuraca V, dkk. A comparison of the results obtained with traditional phlebotomy and with therapeutic erythrocyte pheresis in patients with erythrocytosis. Blood Transfus 2007;5:20-23.
Corrons JLV, Casafont LB, Frasnedo EF. Concise review: how do red blood cells born, live, and die? Ann Hematol 2021;100:2425-33.
Lill MC, Perloff JC, Child JS. Pathogenesis of Thrombocytopenia in Cyanotic Congenital Heart Disease. Am J Cardiol. 2006;98:254-8.
Oechslin E. Management of adults with cyanotic congenital heart disease. Heart 2014;0:1-10. doi:10.1136/heartjnl-2012-301685.
Holsworth RE, Cho YI, Weidman JJ, et al. Cardiovascular benefits of phlebotomy: Relationship to changes in hemorheological variables. Clin Hemorheol Microcirc. 2013;54:271-6.
Tay EL, Peset A, Papaphylactou M, dkk. Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome. Int J Cardiol 2011;151:307-12.
Shelonitda SR, Ashish AS, Donald RH, Parvin S. Cyanotic congenital heart disease (CCHD) with symptomatic erythrocytosis. J Gen Intern Med 2007;22:1775-7.
DOI: http://dx.doi.org/10.14238/sp26.2.2024.125-30
Refbacks
- Saat ini tidak ada refbacks.
##submission.copyrightStatement##
##submission.license.cc.by-nc-sa4.footer##
Email: editorial [at] saripediatri.org
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.